2020.01.02 07:44
2020.01.02 07:47
2020.01.02 08:08
Many people never heard of Lp(a).
Most doctors including cardiologists do not order or include Lp(a)
in the lipid panel screening although the elevated Lp(a) is a known risk
for CVD and one in five has elevated Lp(a) over 30mg% chiefly because
there is no drug or effective therapy for this genetically transmitted CVD risk.
Statins and PCSK9 do not lower Lp(a).
Now for the first time in history we found an agent, antisense, oligonucleotide,
that effectively brings it down in its phase II trial.
This is certainly an exciting news.
We finally found a way conquering the last barrier to reach the goal, i.e.
discovering all the weapons to conquer or prevent atherosclerosis.
2020.01.02 13:14
2020.01.03 01:37
Candidates for Lp(a) screening include 1) premature or family history premature CVD; 2) FH or other genetic lipidemia; 3) recurrent cardiovascular events or rapidly progressive CVD; 4) genetic defects of hemostasis, homocysteine metabolism, as well as diabetes mellitus or autoimmune diseases; 5) ≥ 10% 10-year risk of fatal and/or nonfatal CHD; 6) inadequate LDL-C responses to statin.
No. | Subject | Date | Author | Last Update | Views |
---|---|---|---|---|---|
Notice | How to write your comments onto a webpage [2] | 2016.07.06 | 운영자 | 2016.11.20 | 18185 |
Notice | How to Upload Pictures in webpages | 2016.07.06 | 운영자 | 2018.10.19 | 32334 |
Notice | How to use Rich Text Editor [3] | 2016.06.28 | 운영자 | 2018.10.19 | 5908 |
Notice | How to Write a Webpage | 2016.06.28 | 운영자 | 2020.12.23 | 43827 |
8842 | 훈민정음의 비밀 [3] | 2024.04.25 | 운영자 | 2024.04.26 | 27 |
8841 | 부산정치파동과 미국의 이승만 제거계획 | 2024.04.25 | 온기철*71 | 2024.04.25 | 10 |
8840 | 코너킥으로 웃었다... 황선홍호, 일본 제압하고 8강으로 [5] | 2024.04.22 | 황규정*65 | 2024.04.25 | 28 |
8839 | [시조]懷古歌: 회고가 [1] | 2024.04.21 | 정관호*63 | 2024.04.21 | 10 |
8838 | 부산형무소 살해사건 | 2024.04.20 | 온기철*71 | 2024.04.20 | 17 |
8837 | 육군 방첩대. 미군 CIC, 그리고 김창룡 | 2024.04.17 | 온기철*71 | 2024.04.25 | 19 |
8836 | 김구의 일생과 암살의 원인 | 2024.04.14 | 온기철*71 | 2024.04.25 | 18 |
8835 | OPERA MIGNON: Connais tu le pays [1] | 2024.04.12 | 정관호*63 | 2024.04.12 | 25 |
8834 | “쏘니,너와 함께 뛴건 행운!”, 400경기 감동 축하영상 [5] | 2024.04.06 | 황규정*65 | 2024.04.22 | 32 |
8833 | 길에서 만난 한식 [1] | 2024.04.03 | 정관호*63 | 2024.04.09 | 33 |
8832 | 돌아오는 기러기 [1] | 2024.03.27 | 정관호*63 | 2024.04.18 | 46 |
8831 | 이강인-손흥민 ‘골 합작’ 한국, 태국 3-0 완승…월드컵 최종 예선 진출 성큼 [2] | 2024.03.26 | 황규정*65 | 2024.03.27 | 43 |
8830 | 1945년 8월 15일 오후 강릉 홍제정 안마을에서 [2] | 2024.03.19 | 정관호*63 | 2024.03.24 | 76 |
8829 | 이승만은 왜 김구를 제거 했을까? [1] | 2024.03.17 | 온기철*71 | 2024.03.18 | 52 |
8828 | My Grandson [1] | 2024.03.15 | 노영일*68 | 2024.03.18 | 107 |
8827 | 蜀相(촉상): 촉한 승상 제갈량 [1] | 2024.03.15 | 정관호*63 | 2024.04.12 | 59 |
8826 | 1945년 8월15일에는 서울에 아무일도 없었다. [1] | 2024.03.13 | 온기철*71 | 2024.03.14 | 53 |
8825 | 왕소군 고향에서 [1] | 2024.03.08 | 정관호*63 | 2024.03.20 | 57 |
8824 | 정약용; 늙어가면 친구가 점점 없어진다. [5] | 2024.03.06 | 온기철*71 | 2024.03.08 | 86 |
8823 | Trump is OK to be a candidate. | 2024.03.04 | 온기철*71 | 2024.03.17 | 55 |
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
List of authors.
Abstract
BACKGROUND
Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels.
METHODS
We conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter). Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-LRx, referred to here as APO(a)-LRx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months. The lipoprotein(a) level was measured with an isoform-independent assay. The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses).
RESULTS
The median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter. Administration of APO(a)-LRx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001). There were no significant differences between any APO(a)-LRx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms. The most common adverse events were injection-site reactions.
CONCLUSIONS
APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number b.)